Silva, Thiago Aparecido da 
; Hauser, Paul J.; Bandey, Irfan; Laskowski, Tamara; Wang, Qi; Najjar, Amer M.; Kumaresan, Pappanaicken R.
Fonte: Cytotherapy. Unidade: FMRP
Assuntos: LINFÓCITOS T, FUNGOS, CRIPTOCOCOSE, IMUNOTERAPIA, POLISSACARÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Thiago Aparecido da et al. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. Cytotherapy, v. 23, n. 2, p. 119-130, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.jcyt.2020.11.002. Acesso em: 29 jul. 2024.APA
Silva, T. A. da, Hauser, P. J., Bandey, I., Laskowski, T., Wang, Q., Najjar, A. M., & Kumaresan, P. R. (2021). Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. Cytotherapy, 23( 2), 119-130. doi:10.1016/j.jcyt.2020.11.002NLM
Silva TA da, Hauser PJ, Bandey I, Laskowski T, Wang Q, Najjar AM, Kumaresan PR. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy [Internet]. Cytotherapy. 2021 ; 23( 2): 119-130.[citado 2024 jul. 29 ] Available from: https://doi.org/10.1016/j.jcyt.2020.11.002Vancouver
Silva TA da, Hauser PJ, Bandey I, Laskowski T, Wang Q, Najjar AM, Kumaresan PR. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy [Internet]. Cytotherapy. 2021 ; 23( 2): 119-130.[citado 2024 jul. 29 ] Available from: https://doi.org/10.1016/j.jcyt.2020.11.002
